Russian-made medicines account for up to 72% of public procurement in Russia

12 March 2018

GMP News

In 2017, the public procurement of medicines decreased slightly (with stronger decline in physical rather than monetary terms) and amounted to 340 billion rubles and 0.88 billion packages. These figures were reported in the review of public procurement of medicines for 2017.

Prescription drugs accounted for about 98% of procurement in monetary terms and 90% in physical terms. Russian-made medicines accounted to 72% of procurement in terms of packages or 45% in monetary terms. More than 80% of medicinal products in the public segment (both in monetary and physical terms) are included in the List of Vital and Essential Drugs.

SG Biotech was the most prominent among the manufacturers of drugs shipped to state health facilities following the public procurement. This joint venture between Generium, a Russian biotech company, and Shire, an Irish pharmaceutical company, was registered in Russia in 2016 to supply drugs for hemophilia included in the list of high-cost nosologies. 2017 was a successful year for SG Biotech, as it jumped from 16th to the 9th position in the ranking. Among Top 20 companies, the most significant decline was reported for Celgene, which dropped by 8 positions in the ranking. This is associated with the price reduction for lenalidomide, its flagship INN, caused by the emergence of competitors in the auctions.

Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more